Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Po‐Yao Hsu"'
Autor:
Chih‐Wen Wang, Chung‐Feng Huang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Cheng Liang, Yu‐Ju Wei, Po‐Yao Hsu, Ching‐I. Huang, Ming‐Yen Hsieh, Yi‐Hung Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 40, Iss 5, Pp 477-488 (2024)
Abstract The immune response of patients with chronic liver disease tends to be lower after receiving their second coronavirus disease 2019 (COVID‐19) vaccine dose, but the effect of a third vaccine dose on their immune response is currently unknow
Externí odkaz:
https://doaj.org/article/9264613b93fd4a70ac8cddf8bfe3e0c6
Autor:
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 40, Iss 4, Pp 374-383 (2024)
Abstract The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis‐4
Externí odkaz:
https://doaj.org/article/b2bf93ff14fb4706a81194ac1a7f56e1
Autor:
Tyng‐Yuan Jang, Chi‐Chang Ho, Po‐Cheng Liang, Chih‐Da Wu, Yu‐Ju Wei, Pei‐Chien Tsai, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Meng‐Hsuan Hsieh, Chih‐Wen Wang, Jeng‐Fu Yang, Ming‐Lun Yeh, Chung‐Feng Huang, Wan‐Long Chuang, Jee‐Fu Huang, Ya‐Yun Cheng, Chia‐Yen Dai, Pau‐Chung Chen, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 40, Iss 3, Pp 304-314 (2024)
Abstract We aimed to investigate the association between air pollution and advanced fibrosis among patients with metabolic associated fatty liver disease (MAFLD) and chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A total of 1
Externí odkaz:
https://doaj.org/article/ad783073b7624fa8acbbdc3f0e6d7211
Autor:
Chung‐Feng Huang, Tyng‐Yuan Jang, Shun‐Chieh Yu, Shin‐Chung Huang, Shao‐Lun Ho, Ming‐Lun Yeh, Chih‐Wen Wang, Po‐Cheng Liang, Yu‐Ju Wei, Po‐Yao Hsu, Ching‐I Huang, Ming‐Yen Hsieh, Yi‐Hung Lin, Sung‐Lin Yu, Pey‐Fang Wu, Yu‐Han Chen, Shin‐Chi Chien, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Tso‐Jen Wang, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 40, Iss 1, Pp 86-93 (2024)
Abstract Patients with serious mental illness have a higher risk of hepatitis C virus (HCV) infection but suboptimal HCV care. The current study aimed to facilitate HCV treatment uptake by implementing an integrated outreach care model. Multidiscipli
Externí odkaz:
https://doaj.org/article/5bccbb53c9844936b00c4005a9e34370
Autor:
Ching-I Huang, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Ta-Wei Liu, Yi-Hung Lin, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming-Lung Yu
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 56, Iss 3, Pp 586-597 (2023)
Objectives: Gaps in linkage-to-care remain the barriers toward hepatitis C virus (HCV) elimination in the directly-acting-antivirals (DAA) era, especially during SARS Co–V2 pandemics. We established an outreach project to target HCV micro-eliminati
Externí odkaz:
https://doaj.org/article/ca655321d3d347789df7020ea97abbc9
Autor:
Chung-Feng Huang, Tyng-Yuan Jang, Ping-Hsun Wu, Mei-Chuan Kuo, Ming-Lun Yeh, Chih-Wen Wang, Po-Cheng Liang, Yu-Ju Wei, Po-Yao Hsu, Ching-I Huang, Ming-Yen Hsieh, Yi-Hung Lin, Hui-Hua Hsiao, Chin-Mu Hsu, Chien-Tzu Huang, Chun-Yuan Lee, Yen-Hsu Chen, Tun-Chieh Chen, Kun-Der Lin, Shuo-Hung Wang, Sheng-Fan Wang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Publikováno v:
Virology Journal, Vol 20, Iss 1, Pp 1-7 (2023)
Abstract Background/Aims Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the best policies to control COVID-19 pandemic. The serological response to COVID-19 vaccination in Taiwanese patients with different
Externí odkaz:
https://doaj.org/article/75bec1bb2c354c1a897ea101aa5ab9ab
Autor:
Tyng‐Yuan Jang, Yi‐Hung Lin, Po‐Cheng Liang, Ming‐Lun Yeh, Ching‐I Huang, Ta‐Wei Liu, Yu‐Ju Wei, Po‐Yao Hsu, Jeng‐Fu Yang, Nai‐Jen Hou, Chih‐Wen Wang, Ming‐Yen Hsieh, Zu‐Yau Lin, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 38, Iss 9, Pp 897-906 (2022)
Abstract Hepatitis C virus (HCV) eradication through antivirals ameliorates metabolic profiles. The changes in 2‐h plasma glucose (2HPG) levels by oral glucose tolerance test (OGTT), in chronic hepatitis C (CHC) patients who receive directly acting
Externí odkaz:
https://doaj.org/article/2716a4168f93444f950e751fa2b2f7b4
Autor:
Pei‐Chien Tsai, Chia‐Yen Dai, Ching‐I Huang, Ming‐Lun Yeh, Chung‐Feng Huang, Meng‐Hsuan Hsieh, Jeng‐Fu Yang, Po‐Yao Hsu, Po‐Cheng Liang, Yi‐Hung Lin, Tyng‐Yuan Jang, Ming‐Yen Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang, Wen‐Yu Chang
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 38, Iss 7, Pp 694-702 (2022)
Abstract Understanding the barriers and tackling the hurdles of hepatitis C virus (HCV) care cascades is key to HCV elimination. The current study aimed to investigate the rates of disease awareness, link‐to‐care, and treatment uptake of HCV in a
Externí odkaz:
https://doaj.org/article/e247a605acf147468fa093693bfe2c11
Autor:
Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Ching‐Chih Lin, Kuan‐Yu Chen, Chia‐Yen Dai, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Wan‐Long Chuang, Chung‐Feng Huang, Ming‐Lung Yu
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 104-116 (2022)
Abstract Background and Aims Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors
Externí odkaz:
https://doaj.org/article/8169183efd244c82bda9348fe3369e9a
Autor:
Zu-Yau Lin, Ming-Lun Yeh, Ching-I. Huang, Po-Cheng Liang, Po-Yao Hsu, Shinn-Cherng Chen, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 153, Iss , Pp 113540- (2022)
The advantage of colchicine to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma (HCC) was investigated. Four primary cultured HCC cell lines (S103, S143, S160, S176) were studied by clinically achievable plasma sorafen
Externí odkaz:
https://doaj.org/article/655e4ac2e5e74fd49a67b1e4297ebc2c